



Understanding and Discussing the Implications of FDA's Sentinel Initiative

Grand Hyatt Washington
1000 H Street NW • Washington, DC
October 25, 2011

Attendees

Nayan Acharya Senior Director, Office of Risk Management and Pharmacoepidemiology, Eli Lilly and Co.	Christopher Corsico Senior Vice President, Medicine and Regulatory Affairs, Regional Medical Director, North America, Boehringer Ingelheim Pharmaceuticals, Inc.
Raymond Bain Vice President, Biostatistics and Research Decision Sciences, Merck and Co.	Milbhor D'Silva Vice President Pharmacovigilance and Safety, Astellas Pharma Global Development, Inc.
Robert Ball Director, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration	Rosanne Ferguson Director of Network for Medtronic's Post Approval Network, Medtronic, Inc.
Dorothee B. Bartels Corporate Vice President/Head of Global Epidemiology, Boehringer Ingelheim GmbH and Associate Professor, Hannover Medical School	Thomas P. Gross Acting Director, Office of Surveillance and Biometrics, Center for Devices and Radiological Health (CDRH), U.S. Food and Drug Administration
Donald Beers Associate Chief Counsel for Drugs, U.S. Food and Drug Administration	Ken Hornbuckle Senior Epidemiology Advisor, Office of Risk Management and Pharmacoepidemiology, Global Patient Safety Organization, Eli Lilly and Co.
Carmen Bozic Senior Vice President and Global Head, Safety and Benefit-Risk Management, Biogen Idec	Ralph Horwitz Senior Vice President for Clinical Evaluation Sciences and Senior Advisor to the Chairman of Research and Development, GlaxoSmithKline
Stanley Bukofzer Vice President, Medical and Scientific Affairs, Astellas Pharma US Inc.	Janet Jenkins-Showalters Director, FDA Liaison, Pharmaceutical Development Regulatory, Hoffmann-La Roche/ Genentech
Patrizia Cavazzoni Senior Vice President for Worldwide Safety Strategy, Pfizer Inc.	Juhaeri Juhaeri Senior Director, Global Pharmacovigilance and Epidemiology, Sanofi-Aventis
Henry Che Associate Director, Safety Information Management, Product Safety and Pharmacovigilance, Astellas Pharma Global Development	Erin Karnes Research Associate, Engelberg Center for Health Care Reform, The Brookings Institution
Sally Cluchey Senior Research Associate, Engelberg Center for Health Care Reform, The Brookings Institution	Larry Kocot Deputy Director and Visiting Scholar, Engelberg Center for Health Care Reform, The Brookings Institution

Elias Kouchakji
Executive Medical Director, Global Regulatory Affairs and Safety, Amgen Inc.

Elliott Levy
Senior Vice-President, Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb

Eddie E. Li
Vice President, Regulatory Affairs, Novo Nordisk Inc.

Mary Liu
Post-Doctoral Fellow, Pharmaceutical Development Regulatory, Hoffman-La Roche/Genentech

David Martin
Acting Director, Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration

Mark McClellan
Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, and Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution

Qais A. Mekki
Vice President, Pharmacovigilance, Takeda Global Research and Development Center, Inc.

Robert Meyer
Vice President, Global Regulatory Strategy, Policy and Safety, Merck and Co.

Briggs Morrison
Senior Vice President, Worldwide Medical Excellence, Pfizer Inc.

Garry Neil
Corporate Vice President, Corporate Office of Science and Technology, Johnson & Johnson

Steve Niemcryk
Head, Global Surveillance and Pharmacoepidemiology, Global Pharmacovigilance, Abbott Laboratories

John J. Orloff
Chief Medical Officer and Senior Vice President, Novartis Pharmaceuticals

Sara Palmer
Senior Counsel, Research and Development, Legal Operations, GlaxoSmithKline

Vaishali Patadia
Director and Head, Pharmacoepidemiology, Astellas Pharma Global Development, Inc.

Richard Platt
Professor and Chair, Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute

Melissa Robb
Project Director for the Sentinel Initiative, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration

Patrick Ryan
Associate Director of Analytical Epidemiology, Johnson & Johnson and Co-investigator, Observational Medical Outcomes Partnership

Alfred Sandrock
Senior Vice President, Development, Biogen Idec

Jeffrey Secunda
Vice President, Technology & Regulatory Affairs, AdvaMed

Rachel Sherman
Associate Director for Medical Policy, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration

David Smith
US Regulatory Law Lead, Pfizer Inc.

J. Michael Sprafka
Executive Director, Observational Research, Amgen Inc.

Scott Terrillion
Vice President, Associate General Counsel, Boehringer Ingelheim Pharmaceuticals, Inc.

Michelle Thompson
Senior Director, Regulatory Affairs, Novo Nordisk Inc.

Janet Woodcock
Director, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)